Sign up to save your podcasts
Or
Share Short-and Long-Term Implications of Waiving IP Protections for COVID-19 Related Drugs and Technologies - with Andrei Iancu
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
Short-and Long-Term Implications of Waiving IP Protections for COVID-19 Related Drugs and Technologies - with Andrei Iancu
India, South Africa, and other developing countries are leading the push for a waiver of the Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) under the rationale that it’s the only way to ensure equitable and affordable access to COVID vaccines.
In this episode, Andrei Iancu, former undersecretary of commerce for intellectual property (IP) and director of the USPTO, discusses the Biden Administration’s decision to support the proposed waiver and why waiving certain IP protections for COVID-19 related drugs and products will not deliver the needed equitable and affordable access to COVID vaccines that other countries are hoping for.
View all episodes
By American Consumer Institute
4.3
33 ratings
India, South Africa, and other developing countries are leading the push for a waiver of the Trade-Related Aspects of Intellectual Property Rights (TRIPS Agreement) under the rationale that it’s the only way to ensure equitable and affordable access to COVID vaccines.
In this episode, Andrei Iancu, former undersecretary of commerce for intellectual property (IP) and director of the USPTO, discusses the Biden Administration’s decision to support the proposed waiver and why waiving certain IP protections for COVID-19 related drugs and products will not deliver the needed equitable and affordable access to COVID vaccines that other countries are hoping for.